in the perfusion medium failed to increase glucose uptake by the isolated perfused rat heart, indicating that nonsuppressible insulin-like activity (NSILA) in whole serum was inactive in this system. When NSILA-carrier protein was added to partially purified NSILA-S, its biological activity on the rat heart disappeared. In contrast, the action of insulin was not affected by the presence of NSILA-carrier protein. Binding of lzsI-labelled NSILA-S to rat heart was inhibited by NSILA-carrier protein. 125I-labelled insulin binding was not inhibited. These results support the hypothesis that NSILA-S bound to serum carrier protein is a large molecular compound which does not readily diffuse out of the capillary bed and therefore does not exert insulin-like effects in vivo.
Human serum exerts insulin-like activity on tissues in vitro which is not suppressed by the addition of insulin antibodies [1] . This activity had been shown to reside in a low molecular weight peptide fraction extracted with acid-ethanol (NSILA-S 1, mol. wt. 7500, R.E. Humbel, personal communication) [2, 3] . Further purification resolved NSILA-S into two closely related molecular species which exert almost 1 NSILA: nonsuppressible insulin-like activity of native human serum NSILA-S: nonsuppressible insulin-like activity extracted from human serum with acid-cthanol identical biological effects [4] . The partial amino acid sequence of these two species has been elucidated [51.
It has been puzzling for a long time why NSILA in its native form in blood does not exert insulin-like effects in vivo. A possible explanation was provided by the finding that serum contains a specific high molecular weight carrier protein to which NSILA is tightly bound [6, 7] . The hypothesis was advanced that capillaries constitute a diffusion barrier for the NSILA-carrier-complex and, therefore, prevent its contact with cells.
This hypothesis was tested in the perfused rat heart which is an experimental model in which the biological effects of NSILA-S have been well defined [8, 9, 10] and in which hormones reach the target cells via an intact vascular system.
Materials
Partially purified NSILA-S (3.8 mU/mg) and whale insulin (24 U/mg) (identical to pork insulin) were kindly supplied by Drs. E. Rinderknecht and R. E. Humbel. The NSILA-S preparation used was a mixture of NSILA-S I and NSILA-S II [4] . Molar concentrations of NSILA-S were calculated on the basis of a mol. wt. of 7500 and a specific biological activity of 400 mU/mg for both forms as determined in the fat pad assay with insulin as the reference [4] . t25I-labelled NSILA-S was prepared according to Zapf et al. [11] . 125I-labelled insulin was purchased from CIS (Italy) (specific radioactivity 84 mCi/mg). Heparin (Liquemin) was from ROCHE, Switzerland (5000 USP-U/ml). Human serum albumin, devoid of insulin-like activity, was purchased from the Swiss Red Cross, Berne. Guinea pig anti-insulin serum had an insulin neutralizing capacity of 1 U/ml. 0012-186X/78/0014/0255/$01.00
Methods

Human Serum
Venous blood was taken from normal subjects after an overnight fast. One hour at 4 ~ C was chosen for clotting. After centrifugation, the serum was pooled and stored at -20 ~ C.
NSILA-Carrier Protein
Serum carrier protein for NSILA-S was partially purified according to Zapf et al. [6] . Human serum (60 ml) was applied to a column of Sephadex G-200 (total bed volume 3 1), equilibrated with acetic acid 0.15 mol/l and NaC1 0.15 mol/1. The column effluent between 60% and 80% of the total bed volume was separated into two pools and concentrated by ultrafiltration. The concentrated pools were dialysed extensively agairlst bicarbonate buffer of the same composition as that used for heart perfusion [9] . Relative binding activity for xzsI-labelled NSILA-S was determined according to Zapf et al. [6] . The two pools had binding activities for 125I-labelled NSILA-S of approximately 8 mU/1 (3 • 10 -9 tool/l) and 30 mU/1 (1 x 10 -8 tool/l). For each glucose uptake experiment 1.5 ml of the pool with the higher binding activity was used. The pool (1.5 ml) with the lower binding activity was used for the membrane binding experiments.
Perfusion Experiments
Hearts of fed male ZBZ Cara (formerly OsborneMendel) rats were perfused with Krebs-Ringer bicarbonate buffer gassed with 95% Oz/5% COz, pH 7.4. The technique applied for rat heart perfusion together with some basic metabolic reference data have been reported previously [.8, 9] . Glucose uptake by the perfused rat heart and binding of 125I-labelled hormones were determined as described earlier [9, 10] .
Perfusion with human serum was performed in the presence of heparin (83 USP-U/ml) to prevent formation of fibrin.
NSILA-carrier protein (1.5 ml) was preincub ated for two hours at room temperature with the labelled or unlabelled hormones prior to the perfusion experiment in order to reach binding equilibrium [12] . Krebs-Ringer bicarbonate buffer containing glucose 10 mmol/1 and human serum albumin 2 g/1 was then added to a final volume of 25 ml. The quantity of serum carrier protein required for nearly complete binding of NSILA-S was estimated from the relative binding activities as determined in experiments using 125I-labelled NSILA-S [12] .
All experiments with the labelled hormones were carried out in pairs using the same perfusion fluid, one with and one without added NSILA-carrier protein. Inhibition of membrane binding by NSILA-cartier protein was calculated as per cent of the control. Nonspecific binding was not determined since the large amounts of unlabelled NSILA-S that would have been required were not available. All results are given as means _+ Standard Error of the Mean (SEM). Student's t-test was used for statistical evaluation.
Results
Human serum, diluted ten times with Krebs-Ringer bicarbonate buffer, did not significantly increase glucose uptake by the perfused rat heart above the values obtained in the presence of heparin alone (p > 0.40) (Fig. 1) . The NSILA content of 10% human serum (10-20 rnU/1, 7 • 10 -9 tool/l) [13] would have been high enough to elicit a near maximal response (glucose uptake in the presence of NSILA-S 20 mU/l: 185 +_ 9 ~tmol • g dry wt. -1 • h-l, n = 4). The small amount of insulin present in human serum was neutralized by the addition of guinea pig anti-insulin serum. Heparin itself showed a slight insulin-like effect. The response of the rat heart to insulin and NSILA-S was not changed by heparin.
In the next series of experiments, the rat heart was perfused with NSILA-S in the presence and absence of NSILA-carrier protein. Serum binding protein by itself did not exert insulin-like activity. The results are shown in Figure 2 . NSILA-S at a concentration of 7 X 10 -l~ tool/1 (2 mU/l) significantly increased glucose uptake. The carrier protein abolished the effect of NSILA-S. This inhibition was statistically significant (p < 0.005). Figure 3 shows that the action of insulin was not inhibited by the addition of NSILA-carrier protein (p > 0.5).
Experiments with 125I-labelled NSILA-S showed that its binding to rat heart was inhibited by about 40% in the presence of NSILA-carrier protein ( Table 1) . Binding of le5I-labelled insulin was inhibited only by 10%. The difference between the inhibition of binding of NSILA-S and insulin was statistically significant (p < 0.01), The ten per cent decrease of insulin binding may be explained by nonspecific adsorption to the serum carrier protein fraction during preincubation.
Discussion
Since the first reports on nonsuppressible insulin-like activity of human serum, the paradoxical finding that normal serum contained between 100 and 200 ~tU/ Fig. 1 . Effect of diluted human serum (1 : 10) and insulin (7 • 10 -9 mol/1, 1 U/l) on glucose uptake by the perfused rat heart. NSILA content of 10% serum: 20 mU/1 (7 • 10 -9 tool/l) [13] . Glucose uptake was expressed as ~mol glucose consumed per g dry heart weight per hour. Heparin (83 USP-U/ml) was added to prevent formation of fibrin. Guinea pig anti-insulin serum was present in the experiments with human serum (insulin neutralizing capacity in the perfusion fluid: 2 U/l) --p < 0.01 J ml of non-immunoreactive insulin equivalents without causing hypoglycaemia remained unexplained [13] . Rasio et al. [14] found that concentrations of immunoreactive insulin (IRI) were similar in rat serum and lymph. In contrast, the concentration of insulin-like activity (ILA) in serum was higher than in lymph. Furthermore, they found that ILA of rat serum and NSILA of dog serum were of high , 200 molecular weight [15, 16] . From these results they concluded that NSILA could not diffuse freely from serum to lymph and that it was therefore inactive [16] . Cohen and Nissley [17] demonstrated that rat lymph contained about one-half of the somatomedinlike activity present in serum. Somatomedins belong to the same group of serum peptides with insulin-like activity as NSILA-S. Biirgi et al. [18] found that after gel filtration of human serum on Sephadex G-200 in ammonium acetate 0.1 mol/1 (pH 7.2), nonsuppressible insulin-like activity eluted with a molecular weight between 70000 and 150000. lz5I-labelled NSILA-S injected intravenously into rats was preferentially bound to a serum fraction of approximately 200000 mol. wt. [19] . By using dextran particles of various sizes, Garlick et al. [20] demonstrated that particles with a molecular weight larger than 40 000 did not rapidly leave the vascular system under normal conditions.
Whereas NSILA-S injected into rats was hypoglycaemic [21] , endogenous NSILA did not appear to have any effects on glucose homeostasis. Thus, the hypothesis was put forward that native NSILA with a molecular weight between 70 000 and 150 000 might not readily penetrate the blood vessels and that its bioavailability might, therefore, be restricted [18, 22] . This hypothesis was supported when serum carrier protein for NSILA-S was detected [6, 7] . It was again suggested that the bound form of NSILA-S did not pass the capillary walls and, therefore, was inactive in vivo [6, 19] . The insulin-like activity of whole serum could only be measured in test systems devoid of an intact vascular system as for example in the epididymal fat pad of the rat [13] .
The hypothesis of restricted bioavailability of endogenous NSILA was now tested in the isolated perfused rat heart. This test system provided an organ with an intact vascular network. Moreover, the interaction of NSILA-S with the perfused rat heart has been extensively studied [8, 9, i0] .
The finding that human serum did not stimulate the glucose uptake of perfused rat heart (Figure 1 ) was in accord with the above hypothesis. Although human serum was diluted ten times, the concentration of NSILA would still have been high enough to elicit a near maximal response [8, 13] .
Further support for the hypothesis stated above was obtained from the results of the experiments shown in Figures 2 and 3 , in which the effects of NSILA-S and insulin in the presence and absence of NSILA-carrier protein on the perfused rat heart were compared. In the presence of carrier protein, NSILA-S did not stimulate glucose uptake. The effect of a comparable concentration of insulin was not inhibited by the carrier protein.
In the presence of NSILA-carrier protein, less 125I-labelled NSILA-S was bound to the heart than in its absence (Table 1 ). This finding indicated that 125I-labelled NSILA-S, once bound to serum carrier protein, did not considerably dissociate and that its access to the NSILA-S binding sites on the cell membrane was limited. Binding of azsI-labelled insulin to the heart was not significantly affected by the presence of NSILA-carrier protein.
All these results are compatible with the hypothesis that NSILA-S bound to carrier protein does not readily diffuse through the capillary walls and that it is therefore inactive in vivo. Our results now provide a plausible answer to the question why normoglyeaemia is compatible with the presence of 100 to 200 ~tU of insulin equivalents per ml of human serum.
